



Cite this: RSC Adv., 2019, 9, 5870

 Received 30th November 2018
 Accepted 11th February 2019

 DOI: 10.1039/c8ra09864f
rsc.li/rsc-advances

Introduction

The nitrogen-containing heterocycles occupy an important position in pharmaceuticals and natural products.¹ Furthermore, they exhibit remarkable biological activities, such as anticancer, antileukemic, antiviral, and antifungal properties.² The complexity and diversity of *N*-heterocycles have been employed broadly in the studies of advanced materials and ligands for transition metal catalysis.³ Among reported studies, quinazoline⁴ and indole⁵ derivatives are useful nitrogen-containing heterocyclic compounds, and are core structural motifs of many natural products and pharmaceuticals. Thus heterocyclic compounds bearing these two skeletons most likely possess interesting biological and physicochemical properties.⁶ For example, indoloquinazoline derivatives have been reported to be protein kinase CK2 inhibitors^{6a} and poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.^{6b} 4-(Indole-3-yl)quinazolines have been reported to be potent epidermal growth factor receptor tyrosine kinase inhibitors.^{6c}

Over the past decade, substantial effort has been devoted to the development of reaction conditions for the coupling between quinazoline and indole compounds.⁷ One elegant methodology relies on the nucleophilic substitution of quinazoline chlorides or their analogous with indoles. However, this method cannot be widely employed due to the need for harsh reaction conditions and/or operationally complex protocols. For instance, the substitution reaction between 2,4-dichloroquinazolines and indoles relies on 1.2 equiv. of AlCl_3 (Scheme 1a).^{7a} Additionally, the reaction of quinazoline with indole required Brønsted acid mediator, followed by photocatalyzed


Copper-catalyzed cross-dehydrogenative coupling between quinazoline-3-oxides and indoles[†]

 Qin Yang, Zhiyan Yin, Lifang Zheng, Jianjun Yuan, Song Wei, Qiuping Ding * and Yiyuan Peng 

A novel and simple protocol for the synthesis of 4-(indole-3-yl)quinazolines *via* cross-dehydrogenative coupling of quinazoline-3-oxides and indoles under an air atmosphere has been developed. A series of biheteroaryl products were obtained in moderate to good yields.

aromatization to give the corresponding 4-(indol-3-yl)-quinazoline product in 70% yield (Scheme 1b).^{7d}

On the other hand, we have noticed that cross-dehydrogenative-coupling (CDC) reactions⁸ have emerged as an excellent alternative for the formation of C–C bonds. Furthermore, the *N*-oxide moiety in aza-heteroarene compounds has been recognized as a powerful and removable directing group for *ortho* C–H bond activation.⁹ In the past decade, pyridine *N*-oxides,¹⁰ pyrimidine *N*-oxides,¹¹ quinoline *N*-oxides and isoquinoline *N*-oxides¹² have been extensively employed as useful building block for the preparation of a diverse range of *N*-heterocycles. However, the C4–H functionalization of quinazoline *N*-oxides remains rare.¹³ Therefore, the development of a general and practical strategy for the synthesis of 4-(indole-3-yl)quinazolines *via* CDC reactions of quinazoline *N*-oxides and indoles under mild conditions, is highly desired. Recently, our group has directed its studies to that of the structural elaboration of quinazoline core, with the aim of constructing a quinazoline-based molecular library for bioactivity assays.¹⁴ Herein, we report a copper-catalyzed CDC reaction between the Csp^2 –H of quinazoline-3-oxide and the Csp^2 –H of various indoles for the synthesis of biheteroaryl structures using a mild and operationally simple procedure (Scheme 1c).



Scheme 1 Typical strategies for the synthesis of 4-(indole-3-yl)quinazolines.

Key Laboratory of Functional Small Organic Molecule, Ministry of Education, Jiangxi Province's Key Laboratory of Green Chemistry, Jiangxi Normal University, Nanchang, Jiangxi, 330022, China. E-mail: yypeng@jxnu.edu.cn; dppjxnu@gmail.com

† Electronic supplementary information (ESI) available: Experimental procedure, characterization data, ^1H and ^{13}C NMR spectra of compounds 3. CCDC 1813925 (compound 3ai). For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c8ra09864f



Results and discussion

We initiated our investigation on the model reaction of quinazoline-3-oxide (**1a**) with *N*-methyl-indole (**2a**) in order to optimize the reaction parameters (Table 1). First, the reaction was performed in the presence of 20 mol% CuCl_2 at 60 °C in toluene (Entry 1). To our delight, the desired product **3a** was isolated in a moderate yield of 47%. Encouraged by this preliminary result, we then screened various solvents. The desired product was obtained in moderate or low yields when the reaction was carried out in THF, CH_3CN and DMF (Entries 2–4). Further studies showed that CH_3OH was the best solvent for this transformation, affording the desired product **3a** in 77% yield (Entry 7). Incrementally reducing the catalyst loading from 20 to 5 mol%, showed that 10 mol% catalyst was the optimal amount (Entries 7–9). No transformation took place in the absence of metal catalyst in CH_3OH (Entry 10). Next, further screening of other metal salts was conducted, but no better conditions were discovered (Entries 11–15). Several copper salts were utilized to promote the reaction (Entries 16–20); however, it was found that copper(II) chloride was the most effective. No better result was obtained even at a higher or lower reaction temperature (Entries 21 and 22).

Table 1 Screening of the reaction condition^{a,b}

Entry	Solvent	Catalyst	T/°C	Yield ^c /%
1	Toluene	CuCl_2 (20 mol%)	60	47
2	THF	CuCl_2 (20 mol%)	60	57
3	CH_3CN	CuCl_2 (20 mol%)	60	40
4	DMF	CuCl_2 (20 mol%)	60	32
5	PhCl	CuCl_2 (20 mol%)	60	70
6	DCE	CuCl_2 (20 mol%)	60	75
7	CH_3OH	CuCl_2 (20 mol%)	60	77
8	CH_3OH	CuCl_2 (10 mol%)	60	78
9	CH_3OH	CuCl_2 (5 mol%)	60	67
10	CH_3OH	—	60	ND
11	CH_3OH	$\text{In}(\text{OTf})_3$ (10 mol%)	60	Trace
12	CH_3OH	FeCl_2 (10 mol%)	60	37
13	CH_3OH	FeCl_3 (10 mol%)	60	40
14	CH_3OH	CoCl_2 (10 mol%)	60	20
15	CH_3OH	$\text{Ni}(\text{OTf})_2$ (10 mol%)	60	17
16	CH_3OH	$\text{Cu}(\text{OTf})_2$ (10 mol%)	60	73
17	CH_3OH	$\text{Cu}(\text{acac})_2$ (10 mol%)	60	Trace
18	CH_3OH	CuCl (10 mol%)	60	62
19	CH_3OH	CuBr (10 mol%)	60	73
20	CH_3OH	$\text{Cu}(\text{OAc})_2$ (10 mol%)	60	40
21	CH_3OH	CuCl_2 (10 mol%)	80	53
22	CH_3OH	CuCl_2 (10 mol%)	40	50


^a Optimized conditions are denoted in bold. ^b Reaction conditions: **1a** (0.2 mmol), **2a** (0.3 mmol), catalyst, solvent (2.0 mL), 16 h, under air.

^c Isolated yield.

Under the optimized reaction conditions, the reaction scope was explored, and the results of which are shown in Table 2. The CDC reaction of quinazoline-3-oxides **1** and *N*-methylindole **2a** occurred smoothly to generate the desired products **3** in good yields. When R^2 was an aryl group, both electron-donating and electron-withdrawing substituents on the aryl ring had a slight effect on the reaction (**3aa**–**3ka**), albeit strongly electron-withdrawing substituents, such as the nitro group, greatly retarded the reaction, forming **3ja** in 61% yield. It was observed that an R^2 aliphatic substituent was also tolerated to give the corresponding product **3la** in 72% yield. When the parent quinazoline ring ($\text{R}^2 = \text{H}$) was used, the desired product **3ma** was obtained in 68% yield. Subsequently, R^1 substituents on the phenyl ring moiety of the quinazoline 3-oxide were investigated. Methyl, methoxy, trifluoromethyl, chloro and bromo functionalities were all tolerated, providing the desired products **3na**–**3ra** in 52–84% yields.

Subsequently, the indole scope was examined under the optimized reaction conditions. As shown in Table 3, quinazoline-3-oxide underwent smooth coupling with a variety

Table 2 The reaction of quinazoline-3-oxide **1** with 1-methylindole^a



^a Reaction conditions: **1a** (0.2 mmol), **2a** (0.3 mmol), CuCl_2 (10 mol%), CH_3OH (2.0 mL), 60 °C, under air. ^b Isolated yield.

of substituted indoles. *N*-Methylindoles possessing alkyl, halide, and alkoxy substituents at the 5-position are amenable to the reaction conditions (**3ab**–**3af**), and the expected products were isolated in moderate to good yields. The coupled products were isolated in high yields for *N*-iPr and *N*-Bn substrates (**3ag** and **3ah**). To our surprise, indole itself also proved to be a good coupling partner, providing the corresponding product (**3ai**) in 83% yield. Single-crystal X-ray analysis of **3ai** confirmed its structure and demonstrated the high regioselectivity of the reaction (Fig. 1). In contrast, no desired coupling product was observed for 3-methylindole, which is consistent with selectivity for the C–H activation at the 3-position of the indole (this result is not shown in Table 3). When a CH_3 group is present at the 2-position of the indole, the steric hindrance arising from this substituent influences the reaction; the cross-coupling product **3aj** was obtained in lower yield. However, indoles containing electron-withdrawing *N*-protecting groups, for example, *N*-tosylindole, were not amenable to this transformation, and none of the desired product (**3ak**) was isolated.

The coupled quinazoline-3-oxides products were easily deoxygenated to give the corresponding 4-(indole-3-yl)quinazolines. For example, when **3aa** was treated with PCl_3 (rt, 30 min), clean reduction occurred and **4a** was obtained in 86% yield (Scheme 2).¹⁵ The combination of the described C–H/C–H cross-dehydrogenative-coupling and subsequent reduction provides an attractive and simple procedure for the synthesis of indole-functionalized quinazoline derivatives.

In order to further understand the mechanism of this copper-catalyzed reaction of quinazoline-3-oxide **1** with indole

Table 3 The reaction of quinazoline-3-oxide **1a** with various indoles **2**^a

1a	2	CuCl_2 10 mol% CH_3OH , 60 °C, air	3ab – 3aj ^b
3ab , 76%	3ac , 69%	3ad , 72%	3ae , 78%
3af , 87%	3ag , 88%	3ah , 82%	3ai , 83%
3aj , 58%	3ak , NR		

^a Reaction conditions: **1a** (0.2 mmol), **2a** (0.3 mmol), CuCl_2 (10 mol%), CH_3OH (2.0 mL), 60 °C, under air. ^b Isolated yield.




Fig. 1 X-ray ORTEP illustration of compound **3ai**.


2, three control experiments were conducted (Scheme 3). The desired product was obtained in 84% yield when the reaction was conducted under oxygen atmosphere (Scheme 3a). However, only a trace amount of product **3aa** was obtained when the reaction was carried out under argon, which indicates that oxygen plays a crucial role in this transformation (Scheme 3b). When **1a** was replaced by 2-(*p*-tolyl)quinazoline, the desired product was not obtained (Scheme 3c).

On the basis of these observations and related reports,¹⁶ we have proposed a plausible mechanism for this reaction, as shown in Scheme 4. The CuCl_2 reacts with quinazoline-3-oxide **1a** to form intermediate **A** via C–H activation of **1a**. Next, **A** undergoes an insertion into the 3-position of the C–H bond of **2a** to afford **B**. Oxidation of **B** to $\text{Cu}(\text{III})$ complex **C** occurs via disproportionation with a second equivalent of CuCl_2 , liberating CuCl .¹⁷ **C** undergoes reductive elimination to give the product **3aa** together with $\text{Cu}(\text{I})$, which is reoxidized to $\text{Cu}(\text{II})$ by O_2 and HCl , to complete the cycle.


In conclusion, a novel, simple and efficient protocol for the synthesis of 4-(indole-3-yl)quinazolines via a cross-dehydrogenative coupling of quinazoline-3-oxides and indoles under an air atmosphere has been successfully developed. A series of biheteroaryl products were obtained in moderate to good yields. The unique reactivity and selectivity observed in the CDC reaction prompted us to initiate further studies on the reaction mechanism.

Experimental section


Unless otherwise stated, all commercial reagents were used as received. All solvents were dried and distilled according to standard procedures. Flash column chromatography was performed using silica gel (60 Å pore size, 32–63 mm, standard grade). Analytical thin-layer chromatography was performed using glass plates pre-coated with 0.25 mm 230–400 mesh silica



Scheme 2 Deoxygenation reaction.



Scheme 3 Control experiments.



Scheme 4 Plausible mechanism.

gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were visualized by exposure to ultraviolet light. Organic solutions were concentrated on rotary evaporators at ~ 20 torr at $25\text{--}35$ $^\circ\text{C}$. Nuclear magnetic resonance (NMR) spectra are recorded in parts per million from internal tetramethylsilane on the δ scale. ^1H and ^{13}C NMR spectra were recorded in CDCl_3 on a Bruker DRX-400 spectrometer operating at 400 MHz and 100 MHz, respectively. All chemical shift values are quoted in ppm and coupling constants quoted in Hz.

General experimental procedure for synthesis of 3

The quinazoline-3-oxide (0.2 mmol), indole (0.3 mmol), CuCl_2 (0.02 mmol) and 2.0 mL CH_3OH were mixed in a dry reaction tube. The mixture was stirred at 60 $^\circ\text{C}$ under air for 12–16 hours. After completion of the reaction (monitored by TLC), the mixture was concentrated in vacuum and the residue was purified by flash column chromatography on silica gel with petroleum ether–ethyl acetate as eluent to give the desired product.

4-(1-Methyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3aa). Compound was obtained as a yellow solid: yield 78%; ^1H NMR (400 MHz, CDCl_3) δ 8.30 (s, 1H), 8.22 (d, $J = 8.0$ Hz, 2H), 8.04 (d, $J = 8.0$ Hz, 1H), 7.92 (d, $J = 8.4$ Hz, 1H), 7.69 (td, $J = 7.6, 1.2$ Hz, 1H), 7.52–7.40 (m, 3H), 7.36–7.27 (m, 3H), 7.19 (t, $J = 7.6$ Hz, 1H), 3.94 (s, 3H), 2.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.7, 147.1, 141.2, 140.7, 136.7, 135.5, 130.6, 130.5, 130.3, 128.7, 128.6, 128.0, 127.6, 126.5, 123.1, 122.5, 121.7, 121.0, 110.0, 102.6, 33.6, 21.6. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{24}\text{H}_{20}\text{N}_3\text{O}$: 366.1606, found 366.1609.

4-(1-Methyl-1*H*-indol-3-yl)-2-(*m*-tolyl)quinazoline 3-oxide (3ba). Compound was obtained as a yellow solid: yield 87%; ^1H NMR (400 MHz, CDCl_3) δ 8.32 (s, 1H), 8.12–7.85 (m, 3H), 7.95 (d, $J = 8.4$ Hz, 1H), 7.71 (t, $J = 7.2$ Hz, 1H), 7.54–7.36 (m, 4H), 7.35–7.28 (m, 2H), 7.18 (t, $J = 7.2$ Hz, 1H), 3.95 (s, 3H), 2.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 156.0, 147.1, 141.2, 137.5, 136.7, 135.6, 133.3, 131.2, 130.65, 130.61, 128.8, 128.1, 127.9, 127.6, 127.4, 126.6, 123.2, 122.5, 121.6, 121.0, 110.0, 102.5, 33.6, 21.5. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{24}\text{H}_{20}\text{N}_3\text{O}$: 366.1606, found 366.1607.

4-(1-Methyl-1*H*-indol-3-yl)-2-(*o*-tolyl)quinazoline 3-oxide (3ca). Compound was obtained as a yellow solid: yield 71%; ^1H NMR (400 MHz, CDCl_3) δ 8.43 (s, 1H), 8.11–8.02 (m, 2H), 7.74 (td, $J = 7.2, 1.2$ Hz, 1H), 7.59–7.53 (m, 2H), 7.51–7.43 (m, 2H), 7.43–7.37 (m, 1H), 7.37–7.30 (m, 3H), 7.20 (t, $J = 7.6$ Hz, 1H), 3.92 (s, 3H), 2.35 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 157.8, 146.7, 140.9, 137.1, 136.8, 136.3, 134.1, 130.7, 130.2, 129.6, 128.8, 128.8, 128.3, 127.6, 126.7, 125.8, 123.2, 122.6, 121.7, 121.1, 110.1, 102.4, 33.6, 19.7. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{24}\text{H}_{20}\text{N}_3\text{O}$: 366.1606, found 366.1611.

2-(4-Methoxyphenyl)-4-(1-methyl-1*H*-indol-3-yl)quinazoline 3-oxide (3da). Compound was obtained as a yellow solid: yield 87%; ^1H NMR (400 MHz, CDCl_3) δ 8.46–8.37 (m, 2H), 8.28 (s, 1H), 8.03 (d, $J = 8.0$ Hz, 1H), 7.91 (d, $J = 8.4$ Hz, 1H), 7.70 (td, $J = 7.4, 1.2$ Hz, 1H), 7.51–7.41 (m, 3H), 7.33 (t, $J = 7.6$ Hz, 1H), 7.19 (t, $J = 7.6$ Hz, 1H), 7.05–6.98 (m, 2H), 3.96 (s, 3H), 3.89 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 161.5, 155.1, 147.2, 141.3, 136.7, 135.3, 132.4, 130.6, 128.6, 127.8, 127.6, 126.5, 125.7, 123.0, 122.5, 121.7, 120.9, 113.3, 110.0, 102.7, 55.4, 33.6. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{24}\text{H}_{20}\text{N}_3\text{O}_2$: 382.1556, found 382.1555.

2-(4-Fluorophenyl)-4-(1-methyl-1*H*-indol-3-yl)quinazoline 3-oxide (3ea). Compound was obtained as a yellow solid: yield 83%; ^1H NMR (400 MHz, CDCl_3) δ 8.45–8.35 (m, 2H), 8.30 (s, 1H), 8.05 (d, $J = 8.0$ Hz, 1H), 7.95 (d, $J = 8.0$ Hz, 1H), 7.73 (t, $J = 7.6$ Hz, 1H), 7.51 (t, $J = 7.6$ Hz, 1H), 7.49–7.41 (m, 2H), 7.34 (t, $J = 7.6$ Hz, 1H), 7.23–7.14 (m, 3H), 3.97 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 164.2 (d, $J = 249.2$ Hz), 154.5, 141.2, 136.8, 135.5, 132.8 (d, $J = 8.5$ Hz), 129.4 (d, $J = 3.3$ Hz), 128.7, 128.2, 127.5, 126.6, 123.2, 122.6, 121.6, 121.1, 114.9 (d, $J = 21.6$ Hz), 110.1, 102.5, 33.6. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{23}\text{H}_{17}\text{FN}_3\text{O}$: 370.1356, found 370.1381.

2-(4-Chlorophenyl)-4-(1-methyl-1*H*-indol-3-yl)quinazoline 3-oxide (3fa). Compound was obtained as a yellow solid: yield 82%; ^1H NMR (400 MHz, CDCl_3) δ 8.33 (d, $J = 8.4$ Hz, 2H), 8.28 (s, 1H), 8.05 (d, $J = 8.0$ Hz, 1H), 7.95 (d, $J = 8.4$ Hz, 1H), 7.72 (t, $J = 7.2$ Hz, 1H), 7.55–7.41 (m, 5H), 7.34 (t, $J = 7.4$ Hz, 1H), 7.19 (t, $J = 7.6$ Hz, 1H).





$= 7.4$ Hz, 1H), 3.95 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 154.4, 147.5, 141.2, 136.8, 136.6, 135.5, 131.9, 131.7, 130.9, 128.8, 128.3, 128.1, 127.5, 126.6, 123.2, 122.6, 121.6, 121.1, 110.1, 102.4, 33.6. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{23}\text{H}_{17}\text{ClN}_3\text{O}$: 386.1060, found 386.1075, and 388.1031, found 388.1044.

2-(3-Chlorophenyl)-4-(1-methyl-1*H*-indol-3-yl)quinazoline 3-oxide (3ga). Compound was obtained as a yellow solid: yield 83%; ^1H NMR (400 MHz, CDCl_3) δ 8.35 (t, $J = 1.6$ Hz, 1H), 8.29 (s, 1H), 8.25–8.19 (m, 1H), 8.05 (d, $J = 8.4$ Hz, 1H), 7.95 (d, $J = 8.4$ Hz, 1H), 7.72 (t, $J = 7.6$ Hz, 1H), 7.56–7.40 (m, 5H), 7.33 (t, $J = 7.4$ Hz, 1H), 7.19 (t, $J = 7.6$ Hz, 1H), 3.95 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 154.1, 147.5, 141.1, 136.8, 135.5, 135.0, 133.9, 130.9, 130.5, 130.4, 129.1, 128.9, 128.6, 128.5, 127.5, 126.6, 123.3, 122.6, 121.6, 121.1, 110.1, 102.4, 33.6. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{23}\text{H}_{17}\text{ClN}_3\text{O}$: 386.1060, found 386.1075, and 388.1031, found 388.1045.

2-(4-Bromophenyl)-4-(1-methyl-1*H*-indol-3-yl)quinazoline 3-oxide 3-oxide (3ha). Compound was obtained as a yellow solid: yield 76%; ^1H NMR (400 MHz, CDCl_3) δ 8.28 (s, 1H), 8.25 (d, $J = 8.4$ Hz, 2H), 8.05 (d, $J = 8.4$ Hz, 1H), 7.95 (d, $J = 8.4$ Hz, 1H), 7.73 (t, $J = 7.4$ Hz, 1H), 7.64 (d, $J = 8.8$ Hz, 2H), 7.52 (t, $J = 7.6$ Hz, 1H), 7.48–7.41 (m, 2H), 7.34 (t, $J = 7.6$ Hz, 1H), 7.20 (t, $J = 7.4$ Hz, 1H), 3.96 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 154.5, 147.5, 141.2, 136.8, 135.5, 132.2, 132.1, 131.1, 130.9, 128.8, 128.4, 127.5, 126.6, 125.1, 123.2, 122.6, 121.6, 121.1, 110.1, 102.4, 33.6. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{23}\text{H}_{17}\text{BrN}_3\text{O}$: 430.0555, found 430.0557, and 432.0535, found 432.0537.

4-(1-Methyl-1*H*-indol-3-yl)-2-(4-(trifluoromethyl)phenyl) quinazoline 3-oxide (3ia). Compound was obtained as a yellow solid: yield 93%; ^1H NMR (400 MHz, CDCl_3) δ 8.43 (d, $J = 8.0$ Hz, 2H), 8.31 (s, 1H), 8.07 (d, $J = 8.0$ Hz, 1H), 7.99 (dd, $J = 8.4$, 0.4 Hz, 1H), 7.77–7.73 (m, 3H), 7.55 (td, $J = 7.8$, 1.2 Hz, 1H), 7.46 (t, $J = 8.8$ Hz, 2H), 7.34 (td, $J = 7.8$, 1.2 Hz, 1H), 7.20 (t, $J = 7.8$ Hz, 1H), 3.96 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 154.2, 147.6, 141.2, 136.8, 135.7, 132.0 (q, $J = 32.3$ Hz), 131.0, 130.7, 128.9, 128.7, 127.4, 126.7, 124.8 (q, $J = 3.8$ Hz), 124.0 (q, $J = 207.7$ Hz), 123.4, 122.7, 121.6, 121.2, 110.1, 102.3, 33.6. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{24}\text{H}_{17}\text{F}_3\text{N}_3\text{O}$: 420.1324, found 420.1324.

4-(1-Methyl-1*H*-indol-3-yl)-2-(4-nitrophenyl)quinazoline 3-oxide (3ja). Compound was obtained as a yellow solid: yield 61%; ^1H NMR (400 MHz, CDCl_3) δ 8.58–8.50 (m, 2H), 8.38–8.29 (m, 3H), 8.08 (d, $J = 8.4$ Hz, 1H), 8.00 (d, $J = 8.0$ Hz, 1H), 7.60–7.55 (m, 1H), 7.60–7.55 (m, 1H), 7.48 (d, $J = 8.4$ Hz, 1H), 7.44 (d, $J = 8.0$ Hz, 1H), 7.77 (td, $J = 7.8$, 1.2 Hz, 1H), 7.58 (td, $J = 7.8$, 1.2 Hz, 1H), 7.48 (d, $J = 8.4$ Hz, 1H), 7.44 (d, $J = 8.0$ Hz, 1H), 7.35 (td, $J = 7.6$, 1.0 Hz, 1H), 7.21 (td, $J = 7.6$, 1.0 Hz, 1H), 3.98 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 153.3, 148.7, 141.3, 139.4, 136.8, 135.7, 131.5, 131.3, 129.01, 128.99, 127.4, 126.8, 123.4, 122.9, 122.8, 121.5, 121.3, 110.2, 102.2, 33.7. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{23}\text{H}_{17}\text{N}_4\text{O}_3$: 397.1301, found 397.1276.

4-(1-Methyl-1*H*-indol-3-yl)-2-phenylquinazoline 3-oxide (3ka). Compound was obtained as a yellow solid: yield 79%; ^1H NMR (400 MHz, CDCl_3) δ 8.37–8.22 (m, 3H), 8.07 (d, $J = 8.0$ Hz, 1H), 7.96 (d, $J = 8.0$ Hz, 1H), 7.71 (t, $J = 7.1$ Hz, 1H), 7.58–7.41 (m, 6H), 7.34 (t, $J = 7.2$ Hz, 1H), 7.20 (t, $J = 7.2$ Hz, 1H), 3.95 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.7, 147.1, 141.2, 136.7,

135.6, 133.4, 130.6, 130.4, 130.3, 128.8, 128.1, 127.9, 127.6, 126.6, 123.2, 122.5, 121.6, 121.0, 110.0, 102.5, 33.6. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{23}\text{H}_{18}\text{N}_3\text{O}$: 352.1450, found 352.1437.

2-Ethyl-4-(1-methyl-1*H*-indol-3-yl)quinazoline 3-oxide (3la).

Compound was obtained as a yellow solid: yield 72%; ^1H NMR (400 MHz, CDCl_3) δ 8.22 (s, 1H), 7.98 (d, $J = 8.0$ Hz, 1H), 7.90 (d, $J = 8.4$ Hz, 1H), 7.68 (t, $J = 7.6$ Hz, 1H), 7.51–7.41 (m, 2H), 7.38 (d, $J = 8.0$ Hz, 1H), 7.31 (t, $J = 7.4$ Hz, 1H), 7.16 (t, $J = 7.4$ Hz, 1H), 3.94 (s, 3H), 3.34 (q, $J = 7.2$ Hz, 2H), 1.53 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 161.3, 145.8, 140.7, 136.7, 135.1, 130.4, 122.8, 127.5, 126.5, 122.8, 122.5, 121.6, 120.9, 110.0, 102.5, 33.5, 26.3, 10.3. HRMS (ESI): m/z [M + H] $^+$ calcd for $\text{C}_{19}\text{H}_{18}\text{N}_3\text{O}$: 304.1450, found 304.1456.

4-(1-Methyl-1*H*-indol-3-yl)quinazoline 3-oxide (3ma).

Compound was obtained as a yellow solid: yield 68%; ^1H NMR (400 MHz, CDCl_3) δ 9.10 (s, 1H), 8.26 (s, 1H), 8.14–7.89 (m, 2H), 7.70 (t, $J = 7.6$ Hz, 1H), 7.53 (t, $J = 7.6$ Hz, 1H), 7.44 (d, $J = 8.4$ Hz, 1H), 7.39 (d, $J = 8.0$ Hz, 1H), 7.32 (t, $J = 7.6$ Hz, 1H), 7.17 (t, $J = 7.4$ Hz, 1H), 3.94 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 148.6, 141.5, 136.8, 135.4, 130.8, 128.8, 128.7, 127.2, 126.8, 123.2, 122.7, 121.5, 121.1, 110.1, 101.7, 33.6. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{17}\text{H}_{14}\text{N}_3\text{O}$: 276.1137, found 276.1132.

7-Methyl-4-(1-methyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3na).

Compound was obtained as a yellow solid: yield 71%; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (s, 1H), 8.22 (d, $J = 8.0$ Hz, 2H), 7.82 (d, $J = 8.8$ Hz, 2H), 7.45 (dd, $J = 8.6$, 1.8 Hz, 2H), 7.35–7.27 (m, 4H), 7.18 (t, $J = 7.6$ Hz, 1H), 3.95 (s, 3H), 2.56 (s, 3H), 2.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.6, 147.1, 141.6, 141.5, 140.6, 136.7, 135.5, 130.6, 130.3, 130.1, 128.5, 127.9, 127.6, 126.3, 122.4, 121.6, 121.1, 120.9, 110.0, 102.7, 33.6, 21.8, 21.6. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{25}\text{H}_{22}\text{N}_3\text{O}$: 380.1763, found 380.1767.

6-Methoxy-4-(1-methyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3oa).

Compound was obtained as a yellow solid: yield 52%; ^1H NMR (400 MHz, CDCl_3) δ 8.37 (s, 1H), 8.18 (d, $J = 8.0$ Hz, 2H), 7.95 (d, $J = 9.2$ Hz, 1H), 7.50–7.43 (m, 2H), 7.37–7.27 (m, 4H), 7.22–7.16 (m, 2H), 3.96 (s, 3H), 3.67 (s, 3H), 2.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 158.9, 153.6, 146.0, 140.3, 137.3, 136.7, 135.5, 130.6, 130.3, 130.1, 128.6, 127.2, 124.1, 123.2, 122.4, 121.8, 120.6, 110.1, 104.6, 102.5, 55.7, 33.6, 21.6. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{25}\text{H}_{22}\text{N}_3\text{O}_2$: 396.1712, found 396.1737.

4-(1-Methyl-1*H*-indol-3-yl)-2-(*p*-tolyl)-7-(trifluoromethyl)quinazoline 3-oxide (3pa).

Compound was obtained as a yellow solid: yield 75%; ^1H NMR (400 MHz, CDCl_3) δ 8.37–8.32 (m, 2H), 8.26 (d, $J = 8.0$ Hz, 2H), 8.06 (d, $J = 8.8$ Hz, 1H), 7.64 (dd, $J = 8.8$, 1.6 Hz, 1H), 7.47 (d, $J = 8.4$ Hz, 1H), 7.41 (d, $J = 8.0$ Hz, 1H), 7.37–7.30 (m, 3H), 7.21 (t, $J = 7.6$ Hz, 1H), 3.95 (s, 3H), 2.45 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 157.0, 147.0, 141.5, 140.2, 136.9, 136.0, 132.1 (q, $J = 32.9$ Hz), 130.5, 129.9, 128.8, 127.7, 127.4, 126.5 (q, $J = 4.2$ Hz), 124.6, 123.7 (q, $J = 270.9$ Hz), 123.6 (q, $J = 3.0$ Hz), 122.9, 121.43, 121.40, 110.3, 102.2, 33.7, 21.7. HRMS (ESI ‡): m/z [M + H] $^+$ calcd for $\text{C}_{25}\text{H}_{19}\text{F}_3\text{N}_3\text{O}$: 434.1480, found 434.1478.

6-Chloro-4-(1-methyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3qa).

Compound was obtained as a yellow solid: yield

83%; ^1H NMR (400 MHz, CDCl_3) δ 8.23 (d, J = 8.8 Hz, 3H), 7.97 (d, J = 8.8 Hz, 1H), 7.93 (d, J = 2.0 Hz, 1H), 7.62 (dd, J = 8.8, 2.0 Hz, 1H), 7.46 (d, J = 8.8 Hz, 2H), 7.47–7.29 (m, 3H), 7.22 (t, J = 7.6 Hz, 1H), 3.96 (s, 3H), 2.44 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.9, 146.3, 141.1, 139.4, 136.8, 135.3, 134.0, 131.2, 130.3, 130.1, 131.2, 130.3, 130.1, 128.6, 127.2, 125.0, 124.0, 122.7, 121.4, 121.3, 110.1, 102.3, 33.6, 21.6. HRMS (ESI †): m/z [M + H] $^+$ calcd for $\text{C}_{24}\text{H}_{19}\text{ClN}_3\text{O}$: 400.1217, found 400.1219, and 402.1187, found 402.1188.

6-Bromo-4-(1-methyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3ra). Compound was obtained as a yellow solid: yield 84%; ^1H NMR (400 MHz, CDCl_3) δ 8.31–8.19 (m, 3H), 8.10 (d, J = 1.6 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.75 (dd, J = 8.8, 1.6 Hz, 3H), 7.46 (d, J = 8.4 Hz, 2H), 7.37–7.28 (m, 3H), 7.23 (t, J = 7.6 Hz, 1H), 3.96 (s, 3H), 2.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 156.0, 146.3, 141.1, 139.7, 136.8, 135.3, 133.8, 130.34, 130.29, 130.1, 128.6, 128.3, 127.2, 124.4, 122.8, 122.0, 121.4, 121.3, 110.1, 102.3, 33.6, 21.6. HRMS (ESI †): m/z [M + H] $^+$ calcd for $\text{C}_{24}\text{H}_{19}\text{BrN}_3\text{O}$: 444.0711, found 444.0706, and 446.0691, found 446.0687.

4-(1,5-Dimethyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3ab). Compound was obtained as a yellow solid: yield 76%; ^1H NMR (400 MHz, CDCl_3) δ 8.24 (s, 1H), 8.22 (d, J = 8.4 Hz, 2H), 8.05 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 8.4 Hz, 1H), 7.71 (t, J = 7.6 Hz, 1H), 7.49 (t, J = 7.8 Hz, 1H), 7.34–7.30 (m, 3H), 7.22 (s, 1H), 7.14 (d, J = 8.4 Hz, 1H), 3.92 (s, 3H), 2.43 (s, 3H), 2.40 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.7, 147.3, 141.2, 140.7, 135.4, 135.2, 130.5, 130.4, 130.3, 128.7, 128.6, 127.8, 126.6, 124.1, 123.2, 121.3, 109.7, 102.1, 33.6, 21.63, 21.57. HRMS (ESI †): m/z [M + H] $^+$ calcd for $\text{C}_{25}\text{H}_{21}\text{N}_3\text{O}$: 380.1763, found 380.1762.

4-(5-Methoxy-1-methyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3ac). Compound was obtained as a yellow solid: yield 69%; ^1H NMR (400 MHz, CDCl_3) δ 8.29 (s, 1H), 8.27–8.18 (m, 2H), 8.05 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.71–7.67 (m, 1H), 7.50–7.46 (m, 1H), 7.34–7.30 (m, 3H), 6.97 (dd, J = 8.8, 2.4 Hz, 1H), 6.86 (d, J = 2.0 Hz, 1H), 3.91 (s, 3H), 3.72 (s, 3H), 2.44 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.7, 155.1, 147.1, 141.2, 140.7, 135.8, 131.9, 130.6, 130.5, 130.3, 128.8, 128.6, 128.2, 127.7, 126.6, 122.9, 112.7, 110.7, 103.6, 102.3, 55.8, 33.7, 21.6. HRMS (ESI †): m/z [M + H] $^+$ calcd for $\text{C}_{25}\text{H}_{21}\text{N}_3\text{O}_2$: 396.1712, found 396.1712.

4-(5-Fluoro-1-methyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3ad). Compound was obtained as a yellow solid: yield 72%; ^1H NMR (400 MHz, CDCl_3) δ 8.28 (s, 1H), 8.22 (d, J = 8.0 Hz, 2H), 8.06 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.72 (t, J = 7.4 Hz, 1H), 7.52 (t, J = 7.4 Hz, 1H), 7.38–7.35 (m, 1H), 7.31 (d, J = 7.8 Hz, 2H), 7.15–7.01 (m, 2H), 3.94 (s, 3H), 2.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 158.5 (d, J = 235.5 Hz), 155.7, 146.7, 141.2, 140.9, 136.6, 133.4, 130.7, 130.3, 128.9, 128.6, 128.2, 128.0 (d, J = 10.4 Hz), 126.1, 123.0, 111.2, 110.9, 110.8 (d, J = 9.8 Hz), 107.0 (d, J = 24.8 Hz), 102.8, 33.8, 29.7, 21.6. HRMS (ESI †): m/z [M + H] $^+$ calcd for $\text{C}_{24}\text{H}_{18}\text{FN}_3\text{O}$: 384.1512, found 384.1501.

4-(5-Chloro-1-methyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3ae). Compound was obtained as a yellow solid: yield 78%; ^1H NMR (400 MHz, CDCl_3) δ 8.22 (d, J = 8.4 Hz, 3H), 8.05

(d, J = 8.0 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.71 (t, J = 7.2 Hz, 1H), 7.52 (t, J = 7.2 Hz, 1H), 7.42 (s, 1H), 7.36–7.25 (m, 4H), 3.92 (s, 3H), 2.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.6, 146.5, 141.2, 140.9, 136.2, 135.2, 130.8, 130.3, 128.9, 128.6, 128.5, 128.3, 127.0, 126.0, 123.1, 123.0, 121.1, 111.0, 102.4, 33.7, 21.6. HRMS (ESI †): m/z [M + H] $^+$ calcd for $\text{C}_{24}\text{H}_{18}\text{ClN}_3\text{O}$: 400.1217, found 400.1219, and 402.1187, found 402.1188.

4-(5-Bromo-1-methyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3af). Compound was obtained as a yellow solid: yield 87%; ^1H NMR (400 MHz, CDCl_3) δ 8.22 (d, J = 8.0 Hz, 1H), 8.19 (s, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.71 (t, J = 6.8 Hz, 1H), 7.57 (s, 1H), 7.52 (t, J = 7.2 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 8.0 Hz, 3H), 3.92 (s, 3H), 2.43 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.6, 146.5, 141.2, 140.9, 136.1, 135.5, 130.8, 130.3, 129.1, 128.9, 128.6, 128.3, 126.0, 125.5, 124.1, 123.1, 114.5, 111.5, 102.4, 100.0, 33.7, 21.6. HRMS (ESI †): m/z [M + H] $^+$ calcd for $\text{C}_{23}\text{H}_{18}\text{BrN}_3\text{O}$: 444.0711, found 444.0710, and 446.0691, found 446.0690.

4-(1-Isopropyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3ag). Compound was obtained as a yellow solid: yield 88%; ^1H NMR (400 MHz, CDCl_3) δ 8.46 (s, 1H), 8.19 (d, J = 8.0 Hz, 2H), 8.05 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 8.4 Hz, 1H), 7.70 (t, J = 7.4 Hz, 1H), 7.56–7.44 (m, 3H), 7.36–7.28 (m, 3H), 7.18 (t, J = 7.4 Hz, 1H), 4.90–4.75 (m, 1H), 2.44 (s, 3H), 1.67 (s, 3H), 1.65 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.9, 147.4, 141.3, 140.6, 135.7, 131.0, 130.61, 130.55, 130.2, 128.7, 128.6, 127.9, 127.8, 126.7, 123.2, 122.2, 121.9, 120.9, 110.3, 102.8, 48.1, 22.8, 21.6. HRMS (ESI): m/z [M + H] $^+$ calcd for $\text{C}_{26}\text{H}_{24}\text{N}_3\text{O}$: 394.1919, found 394.1919.

4-(1-Benzyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3ah). Compound was obtained as a yellow solid: yield 82%; ^1H NMR (400 MHz, CDCl_3) δ 8.33 (s, 1H), 8.22 (d, J = 7.6 Hz, 2H), 8.04 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.68 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 8.2 Hz, 2H), 7.40 (d, J = 8.0 Hz, 1H), 7.37–7.21 (m, 7H), 7.17 (t, J = 7.4 Hz, 1H), 5.45 (s, 2H), 2.42 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.8, 147.0, 141.1, 140.7, 136.3, 134.8, 130.53, 130.47, 130.3, 129.0, 128.8, 128.6, 128.1, 128.0, 127.2, 126.4, 123.2, 122.6, 121.9, 121.1, 110.6, 103.4, 51.0, 21.6. HRMS (ESI †): m/z [M + H] $^+$ calcd for $\text{C}_{30}\text{H}_{24}\text{N}_3\text{O}$: 442.1919, found 442.1935.

4-(1-Indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3ai). Compound was obtained as a yellow solid: yield 83%; ^1H NMR (400 MHz, CDCl_3) δ 10.24 (s, 1H), 8.28 (d, J = 7.2 Hz, 2H), 8.05 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.71 (t, J = 7.2 Hz, 1H), 7.57–7.39 (m, 3H), 7.33 (d, J = 7.6 Hz, 2H), 7.08 (s, 3H), 2.44 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.5, 148.5, 141.5, 140.9, 136.1, 131.1, 131.0, 130.5, 130.4, 128.7, 128.6, 128.3, 126.6, 126.3, 123.5, 122.4, 121.4, 120.8, 112.3, 103.5, 21.6. HRMS (ESI †): m/z [M + H] $^+$ calcd for $\text{C}_{23}\text{H}_{18}\text{N}_3\text{O}$: 352.1450, found 352.1447.

4-(2-Methyl-1*H*-indol-3-yl)-2-(*p*-tolyl)quinazoline 3-oxide (3aj). Compound was obtained as a yellow solid: yield 58%; ^1H NMR (400 MHz, CDCl_3) δ 9.55 (s, 1H), 8.31 (d, J = 8.0 Hz, 2H), 8.06 (d, J = 8.4 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 7.7 Hz, 1H), 7.05 (s, 3H), 2.43 (s, 3H), 2.04 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.7, 149.4, 141.03, 140.99, 139.7,



136.1, 130.8, 130.50, 130.45, 128.7, 128.5, 127.7, 126.6, 124.2, 121.4, 120.2, 119.5, 111.7, 101.3, 21.6, 13.7. HRMS (ESI): m/z [M + H]⁺ calcd for C₂₄H₂₀N₃O: 366.1606, found 366.1602.

4-(1-Methyl-1H-indol-3-yl)-2-(p-tolyl)quinazoline (4a). Compound was obtained as an off-white solid: yield 86%; ¹H NMR (400 MHz, CDCl₃) δ 8.64 (d, J = 8.4 Hz, 2H), 8.37 (d, J = 8.4 Hz, 2H), 8.11 (d, J = 8.4 Hz, 1H), 7.85 (td, J = 7.0, 1.2 Hz, 1H), 7.76 (s, 1H), 7.53 (td, J = 7.6, 0.8 Hz, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.42–7.31 (m, 4H), 3.94 (s, 3H), 2.46 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 160.4, 152.1, 140.4, 137.6, 136.1, 133.0, 132.7, 129.3, 129.1, 128.6, 127.4, 126.8, 126.3, 123.0, 122.1, 121.8, 121.4, 113.4, 109.7, 33.4, 21.54. HRMS (ESI): m/z [M + H]⁺ calcd for C₂₄H₁₉N₃: 350.1657, found 350.1656.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Financial support from National Natural Science Foundation of China (no. 21762020 and 21362014), Jiangxi Provincial Department of Science and Technology (no. 2017BAB203006), and Key Laboratory of Functional Small Organic Molecule, Ministry of Education, Jiangxi Normal University (no. KLFS-KF-201623) is gratefully acknowledged.

Notes and references

- (a) A. F. Pozharskii, A. T. Soldartenkov, and A. R. Katritzky, *Heterocycles in Life and Society*, John Wiley & Sons, Weinheim, 2nd edn, 2011; (b) W. R. Pitt, D. M. Parry, B. G. Perry and C. R. Groom, *J. Med. Chem.*, 2009, **52**, 2952; (c) S. Bongarzone and M. L. Bolognesi, *Expert Opin. Drug Discovery*, 2011, **6**, 251; (d) J. Polanski, A. Kurczyk, A. Bak and R. Musiol, *Curr. Med. Chem.*, 2012, **19**, 1921.
- (a) P. Y. Chung, Z. X. Bian, H. Y. Pun, D. Chan, A. S. C. Chan, C. H. Chui and K. H. Lam, *Future Med. Chem.*, 2015, **7**, 947; (b) A. M. Mfuh and O. V. Larionov, *Curr. Med. Chem.*, 2015, **22**, 2819.
- (a) G. Hughes and M. R. Bryce, *J. Mater. Chem.*, 2005, **15**, 94; (b) A. Kimyonok, X. Y. Wang and M. Week, *J. Macromol. Sci., Polym. Rev.*, 2006, **46**, 47.
- For selected reviews, see: (a) D. Connolly, D. Cusack, T. O'Sullivan and P. Guiry, *Tetrahedron*, 2005, **61**, 10153; (b) J. Michael, *Nat. Prod. Rep.*, 2007, **24**, 223; (c) S. Mhaske and N. Argade, *Tetrahedron*, 2006, **62**, 9787.
- (a) G. R. Humphrey and J. T. Kuethe, *Chem. Rev.*, 2006, **106**, 2875; (b) M. Bandini and A. Eichholzer, *Angew. Chem., Int. Ed.*, 2009, **48**, 9608; (c) A. J. Kochanowska-Karamyan and M. T. Hamann, *Chem. Rev.*, 2010, **110**, 4489.
- (a) E. Vangrevelinghe, K. Zimmermann, J. Schoepfer, R. Portmann, D. Fabbro and P. Furet, *J. Med. Chem.*, 2003, **46**, 2656; (b) D. V. Ferraris, *J. Med. Chem.*, 2010, **53**, 4561; (c) A. Lüth and W. Löwe, *Eur. J. Med. Chem.*, 2008, **43**, 1478; (d) Y. Rao, H. Liu, L. Gao, H. Yu, J. H. Tan, T. M. Ou, S. L. Huang, L. Q. Gu, J. M. Ye and Z. S. Huang, *Bioorg. Med. Chem.*, 2015, **23**, 4719.
- (a) S. Kumar and D. P. Sahu, *J. Heterocycl. Chem.*, 2009, **46**, 748; (b) Y. A. Azev, S. V. Shorshnev and B. V. Golomolzin, *Tetrahedron Lett.*, 2009, **50**, 2899; (c) M. Staderini, M. L. Bolognesi and J. C. Menéndez, *Adv. Synth. Catal.*, 2015, **357**, 185; (d) I. A. Utepova, M. A. Trestsova, O. N. Chupakhin, V. N. Charushin and A. A. Rempel, *Green Chem.*, 2015, **17**, 4401; (e) O. N. Chupakhin, A. V. Shchepochkin and V. N. Charushin, *Green Chem.*, 2017, **19**, 2931.
- (a) C.-J. LI, *Acc. Chem. Res.*, 2009, **42**, 335; (b) C. Liu, H. Zhang, W. Shi and A. Lei, *Chem. Rev.*, 2011, **111**, 1780; (c) C. L. Sun, B. J. Li and Z. J. Shi, *Chem. Rev.*, 2011, **111**, 1293; (d) Y. Yang, J. Lan and J. You, *Chem. Rev.*, 2017, **117**, 8787; (e) W. Hu and Y. Long, *Chin. J. Org. Chem.*, 2017, **37**, 2850.
- For recent reviews: (a) G. Yan, A. J. Borah and M. Yang, *Adv. Synth. Catal.*, 2014, **356**, 2375; (b) L. Yali, Z. Yunhui, F. Hongyan and J. Xinhua, *Chin. J. Org. Chem.*, 2013, **33**, 267; (c) W. Ma, P. Gandeepan, J. Li and L. Ackermann, *Org. Chem. Front.*, 2017, **4**, 1435.
- (a) X. Gong, G. Song, H. Zhang and X. Li, *Org. Lett.*, 2011, **13**, 1766; (b) M. Li, X. Li, H. Chang, W. Gao and W. Wei, *Org. Biomol. Chem.*, 2016, **14**, 2421; (c) A. Lehecq, K. Rousée, C. Schneider, V. Levacher, C. Hoarau, X. Pannecoucke and S. Couve-Bonnaire, *Eur. J. Org. Chem.*, 2017, **21**, 3049.
- (a) J. P. Leclerc and K. Fagnou, *Angew. Chem., Int. Ed.*, 2006, **45**, 7781; (b) D. J. Schipper, M. El-salfiti, C. J. Whipp and K. Fagnou, *Tetrahedron*, 2009, **65**, 4977; (c) J. M. Keith, *J. Org. Chem.*, 2010, **75**, 2722; (d) J. M. Keith, *J. Org. Chem.*, 2012, **77**, 11313; (e) L. A. Galliamova, M. V. Varaksin, O. N. Chupakhin, P. A. Slepukhin and V. N. Charushin, *Organometallics*, 2015, **34**, 5285; (f) A. P. Colleville, R. A. Horan, S. Olazabal and N. C. Tomkinson, *Org. Process Res. Dev.*, 2016, **20**, 1283; (g) F. Roudesly, L. F. Veiros, J. Oble and G. Poli, *Org. Lett.*, 2018, **20**, 2346.
- (a) T. Nishida, H. Ida, Y. Kuninobu and M. Kanai, *Nat. Commun.*, 2014, **5**, 3387; (b) Y. Kuninobu, M. Nagase and M. Kanai, *Angew. Chem., Int. Ed.*, 2015, **54**, 10263; (c) X. Y. Zhang, Z. S. Qi and X. W. Li, *Angew. Chem., Int. Ed.*, 2014, **53**, 10794; (d) H. Hwang, J. Kim, J. Jeong and S. Chang, *J. Am. Chem. Soc.*, 2014, **136**, 10770; (e) Q. Xiao, J. Sheng, Q. Ding and J. Wu, *Eur. J. Org. Chem.*, 2014, **1**, 217; (f) K. Shin, S. W. Park and S. Chang, *J. Am. Chem. Soc.*, 2015, **137**, 8584; (g) X. Chen, X. Cui and Y. Wu, *Org. Lett.*, 2016, **18**, 3722; (h) D. E. Stephens, J. Lakey-Beitia, A. C. Atesin, T. A. Atesin, G. Chavez, H. D. Arman and O. V. Larionov, *ACS Catal.*, 2015, **5**, 167; (i) B. Yao, C. L. Deng, Y. Liu, R. Y. Tang, X. G. Zhang and J. H. Li, *Chem. Commun.*, 2015, **51**, 4097; (j) N. Barsu, M. Sen, J. R. Premkumar and B. Sundararaju, *Chem. Commun.*, 2016, **52**, 1338; (k) D. Y. Li, Z. L. Huang and P. N. Liu, *Org. Lett.*, 2018, **20**, 2028.
- (a) L. Fan, T. Wang, Y. Tian, F. Xiong, S. Wu, Q. Liang and J. Zhao, *Chem. Commun.*, 2016, **52**, 5375; (b) Q. Yang, M. Lou, Z. Yin, Z. Deng, Q. Ding and Y. Peng, *Org. Biomol. Chem.*, 2018, **16**, 8724.



- 14 (a) Y. Y. Peng, G. Y. S. Qiu, Q. Yang, J. J. Yuan and Z. H. Deng, *Synthesis*, 2012, **44**, 1237; (b) G. Y. S. Qiu, P. Huang, Q. Yang, H. Lu, J. Xu, Z. Deng, M. Zhang and Y. Y. Peng, *Synthesis*, 2013, **45**, 3131; (c) X. Chen, Q. Yang, Y. R. Zhou, Z. H. Deng, X. C. Mao and Y. Y. Peng, *Synthesis*, 2015, **47**, 2055; (d) X. Zhao, Y. Zhou, Y. Xie, Q. Ding, Z. Deng, M. Zhang, J. Xu and Y. Y. Peng, *Synthesis*, 2013, **45**, 3245; (e) Y. Y. Peng, P. Huang, Y. Wang, Y. R. Zhou, J. J. Yuan, Q. Yang, X. Jiang, Z. Deng and J. S. Xu, *Org. Biomol. Chem.*, 2014, **12**, 5922; (f) C. Zhang, Y. Zhou, Z. Deng, X. Chen and Y. Y. Peng, *Eur. J. Org. Chem.*, 2015, **8**, 1735; (g) X. L. Ye, Z. H. Yuan, Y. R. Zhou, Q. Yang, Y. P. Xie, Z. H. Deng and Y. Y. Peng, *J. Heterocycl. Chem.*, 2016, **53**, 1956; (h) X. L. Ye, J. J. Yuan, Y. R. Zhou, Z. H. Deng, X. C. Mao and Y. Y. Peng, *Synthesis*, 2016, **48**, 3976; (i) M. Lou, Z. Deng, X. Mao, Y. Fu, Q. Yang and Y. Peng, *Org. Biomol. Chem.*, 2018, **16**, 1851.
- 15 S. H. Cho, S. J. Hwang and S. Chang, *J. Am. Chem. Soc.*, 2008, **130**, 9254.
- 16 (a) M. Kitahara, N. Umeda, K. Hirano, T. Satoh and M. Miura, *J. Am. Chem. Soc.*, 2011, **133**, 2160; (b) S. Fan, Z. Chen and X. Zhang, *Org. Lett.*, 2012, **14**, 4950; (c) R. Odani, K. Hirano, T. Satoh and M. Miura, *J. Org. Chem.*, 2013, **78**, 11045.
- 17 (a) A. E. King, T. C. Brunold and S. S. Stahl, *J. Am. Chem. Soc.*, 2009, **131**, 5044; (b) A. M. Suess, M. Z. Ertem, C. J. Cramer and S. S. Stahl, *J. Am. Chem. Soc.*, 2013, **135**, 9797; (c) J. C. Vantourout, H. N. Miras, A. Isidro-Llobet, S. Sproules and A. J. Watson, *J. Am. Chem. Soc.*, 2017, **139**, 4769.

